Welcome to our dedicated page for Puma Biotechnology SEC filings (Ticker: PBYI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Puma Biotechnology, Inc. (PBYI) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Puma is a Nasdaq-listed biopharmaceutical company focused on oncology, and its filings offer detailed insight into the commercialization of NERLYNX (neratinib) and the development of alisertib, as well as its broader financial and corporate position.
Through periodic and current reports, investors can review Puma’s quarterly and annual financial statements, including revenue from NERLYNX product sales, royalty revenue, operating costs and expenses, and research and development spending tied to programs such as the ALISCA-Lung1 and ALISCA-Breast1 Phase II trials. Forms 8-K furnish press releases on quarterly results and disclose items such as amendments to the company’s bylaws, giving context on governance and legal structure.
This page also surfaces any proxy statements and related governance documents, where available, that describe board composition, compensation policies, and equity incentive plans such as Puma’s 2017 Employment Inducement Incentive Award Plan. Form 4 and other insider transaction filings, when present, can help users monitor share transactions by directors and officers.
Stock Titan enhances Puma’s SEC filings with AI-powered summaries that highlight key points from lengthy 10-K and 10-Q reports, explain complex accounting or clinical development disclosures in plain language, and flag notable risk factor or pipeline updates. Real-time integration with EDGAR helps ensure that new PBYI filings, including material 8-Ks, appear promptly, allowing investors, analysts, and researchers to quickly understand how regulatory, financial, and clinical developments may affect Puma Biotechnology’s business and PBYI stock.
Form 4 filing overview: Puma Biotechnology (PBYI) Chief Financial Officer Maximo F. Nougues reported two open-market sales of company common stock executed on 07/08/2025 and 07/09/2025.
- Shares sold: 5,587 shares at $3.533 on 07/08/2025 and 3,935 shares at $3.535 on 07/09/2025, totalling 9,522 shares.
- Proceeds: Approximately $33,600 based on the disclosed sale prices.
- Post-sale ownership: 204,229 shares held directly after the second transaction, down from an estimated 213,751 shares before the first sale—an ownership reduction of roughly 4.5%.
- Rule 10b5-1 plan: The filing states the transactions were effected under a pre-established Rule 10b5-1(c) trading plan adopted on 12-14-2020.
The reported activity is routine insider selling rather than a grant or option exercise. Because the sales were pre-planned and represent a modest fraction of the CFO’s remaining stake, the market impact is typically viewed as neutral to slightly negative; insider sales can raise questions about confidence, but the use of a long-standing 10b5-1 plan mitigates concerns of opportunistic timing.
Puma Biotechnology, Inc. (PBYI) Form 4 filing: Senior Vice President of Regulatory Affairs Douglas M. Hunt disclosed two open-market sales executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on 12-14-2020.
- 07/08/2025: Sold 4,374 common shares at $3.533; post-sale holding 168,337 shares.
- 07/09/2025: Sold 3,443 common shares at $3.535; post-sale holding 164,894 shares.
The transactions total 7,817 shares (~4.6% of his reported direct ownership) and were filed by one reporting person. No derivative transactions were reported. Hunt remains an officer of the company.
Puma Biotechnology, Inc. (Nasdaq: PBYI) filed a Form 8-K announcing that its Board of Directors approved and adopted Fifth Amended and Restated Bylaws on June 19, 2025. The revisions align the company’s corporate governance documents with recent updates to Delaware corporate law and include conforming and ministerial edits. No changes to the company’s fiscal year, capital structure, or financial guidance were disclosed. The amended bylaws are filed as Exhibit 3.1 and incorporated by reference.